BioSpace News Archive

An analysis of efficacy outcomes by causative pathogens showed that clinical and microbiologic response rates for Zerbaxa were comparable to meropenem for Gram-negative respiratory tract pathogens.

Janssen’s Invokana could become the first diabetes medication to demonstrate reduction in progression to end-stage renal failure in Type 2 diabetes patients with chronic kidney disease.

Stephen Quake, a Stanford University bioengineer and inventor, recently shared several years’ worth of email communications between himself and He with The New York Times.

The $13.8 million facility that will include training sites, biotech wet laboratories, clean rooms, and office and event spaces is now looking for organizations and companies to fill the space.

MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has further expanded the clinical development of guselkumab) into familial adenomatous polyposis, a disease of the gastrointestinal tract.

Major framework agreement signed with Life Healthcare Distribution (“LHC”) for the exclusive distribution of HEMOBLAST Bellows in the sizeable and growing Australian market

For decades, independently owned pharmacies have maintained a reputation for locally rooted, personalized service.

International law firm McDermott Will & Emery has launched its new Compliance Toolkit and Checkup program for Physician Practice Management (PPM) organizations.

Ian Jenkins, CEO of Frelii Inc. (OTCQB: FRLI) (“Frelii” or “The Company”) met in an informal meeting with Canadian Prime Minister, Justin Trudeau to discuss how Frelii’s artificial intelligence (AI) technology could be beneficial in advancing the safe and more effective use of medical cannabis products in Canada.

AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its Annual Report for 2018 is now available on the company’s website, www.alzecurepharma.se.